[go: up one dir, main page]

CL2012001539A1 - Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo. - Google Patents

Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.

Info

Publication number
CL2012001539A1
CL2012001539A1 CL2012001539A CL2012001539A CL2012001539A1 CL 2012001539 A1 CL2012001539 A1 CL 2012001539A1 CL 2012001539 A CL2012001539 A CL 2012001539A CL 2012001539 A CL2012001539 A CL 2012001539A CL 2012001539 A1 CL2012001539 A1 CL 2012001539A1
Authority
CL
Chile
Prior art keywords
antibody
nucleic acid
acid sequence
pharmaceutical composition
host cell
Prior art date
Application number
CL2012001539A
Other languages
English (en)
Inventor
Christiane Otto
Siegmund Wolf
Christoph Freiberg
Axel Harrenga
Simone Greven
Mark Trautwein
Sandra Bruder
Eicker
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001539(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2012001539A1 publication Critical patent/CL2012001539A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpo 005-C04 que antagonizan la señalización mediada por el receptor de prolactina; secuencia de ácido nucleico que codifica dicho anticuerpo; vector de expresión y célula huésped que comprenden dicha secuencia de ácido nucleico; uso del anticuerpo para terapia hormonal combinada; composición farmacéutica que comprende el anticuerpo.
CL2012001539A 2009-12-10 2012-06-08 Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo. CL2012001539A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075546A EP2332995A1 (en) 2009-12-10 2009-12-10 Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (1)

Publication Number Publication Date
CL2012001539A1 true CL2012001539A1 (es) 2012-10-12

Family

ID=42091520

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012001539A CL2012001539A1 (es) 2009-12-10 2012-06-08 Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
CL2012001540A CL2012001540A1 (es) 2009-12-10 2012-06-08 Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2012001540A CL2012001540A1 (es) 2009-12-10 2012-06-08 Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina.

Country Status (40)

Country Link
US (6) US20130171147A1 (es)
EP (13) EP2332995A1 (es)
JP (7) JP2013513559A (es)
KR (2) KR101765968B1 (es)
CN (6) CN102858801A (es)
AP (1) AP2012006343A0 (es)
AR (6) AR079351A1 (es)
AU (2) AU2010330161B2 (es)
BR (2) BR112012015852B8 (es)
CA (6) CA2783651A1 (es)
CL (2) CL2012001539A1 (es)
CR (2) CR20120310A (es)
CU (2) CU23973B1 (es)
CY (2) CY1118209T1 (es)
DK (2) DK2510002T3 (es)
DO (2) DOP2012000159A (es)
EA (2) EA029327B1 (es)
EC (2) ECSP12011966A (es)
ES (2) ES2603352T3 (es)
GT (1) GT201200186A (es)
HR (2) HRP20170016T1 (es)
HU (2) HUE031631T2 (es)
IL (2) IL220151A0 (es)
IN (2) IN2012DN05082A (es)
LT (2) LT2510002T (es)
MA (1) MA33888B1 (es)
ME (1) ME02577B (es)
MX (2) MX2012006621A (es)
NZ (2) NZ600512A (es)
PE (3) PE20121561A1 (es)
PH (2) PH12012501129A1 (es)
PL (2) PL2510002T3 (es)
PT (2) PT2510006T (es)
RS (2) RS55277B1 (es)
SG (2) SG181513A1 (es)
SI (2) SI2510002T1 (es)
TN (1) TN2012000294A1 (es)
TW (5) TWI508744B (es)
WO (6) WO2011069796A1 (es)
ZA (2) ZA201204213B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
SG11201405468QA (en) 2012-03-14 2014-10-30 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
MX382301B (es) 2012-12-24 2025-03-13 Abbvie Inc Proteinas de union al receptor de prolactina y usos de las mismas.
CA2906101A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
KR20170063881A (ko) 2014-10-02 2017-06-08 시티 오브 호프 다가 메디토프, 메디토프 결합 항체 및 이의 용도
KR20170105558A (ko) * 2015-01-30 2017-09-19 각코우호우징 사이타마이카다이가쿠 항 alk2 항체
KR20180025865A (ko) 2015-07-06 2018-03-09 리제너론 파마슈티칼스 인코포레이티드 다중특이적 항원 결합 분자 및 이의 용도
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
CA3062880A1 (en) * 2017-05-12 2018-11-15 Millennium Pharmaceuticals, Inc. Treatment of gastroparesis with triazaspiro[4.5]decanone
KR20200027494A (ko) 2017-07-10 2020-03-12 바이엘 파마 악티엔게젤샤프트 남성 및 여성 패턴 탈모를 위한 프로락틴 수용체 항체
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN118834297A (zh) * 2023-04-24 2024-10-25 深圳真实生物医药科技有限公司 泌乳素受体抗体及其用途
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP2001500865A (ja) * 1996-09-13 2001-01-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 避妊の非ホルモン法
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
AU2003300904A1 (en) * 2002-12-13 2004-07-09 The Ohio State University Antagonists for human prolactin
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
JP4954709B2 (ja) * 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
EP3018144A1 (en) * 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
WO2009013621A2 (en) 2007-05-30 2009-01-29 Auckland Uniservices Limited Inhibitors for growth hormone and related hormones, and methods of use thereof
EP2025683A1 (en) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Also Published As

Publication number Publication date
AR079350A1 (es) 2012-01-18
AR079349A1 (es) 2012-01-18
CN102884082B (zh) 2015-05-20
ECSP12011965A (es) 2012-07-31
PT2510006T (pt) 2017-01-20
PH12012501129A1 (en) 2012-11-05
NZ600512A (en) 2014-11-28
JP2013513559A (ja) 2013-04-22
BR112012014048B1 (pt) 2021-10-26
IL220151A0 (en) 2012-07-31
HUE030143T2 (en) 2017-04-28
DOP2012000159A (es) 2012-09-30
MA33888B1 (fr) 2013-01-02
CU20120093A7 (es) 2012-10-15
AP2012006343A0 (en) 2012-06-30
CN102858801A (zh) 2013-01-02
JP2013513363A (ja) 2013-04-22
SI2510006T1 (sl) 2017-02-28
CR20120310A (es) 2012-08-01
DK2510006T3 (en) 2017-01-23
MX2012006621A (es) 2012-10-05
SG181513A1 (en) 2012-07-30
WO2011069794A1 (en) 2011-06-16
TW201130507A (en) 2011-09-16
CA2783513C (en) 2018-08-14
GT201200186A (es) 2014-01-06
EA029327B1 (ru) 2018-03-30
CA2783610A1 (en) 2011-06-16
BR112012015852B8 (pt) 2021-05-25
ES2610654T3 (es) 2017-04-28
AU2010330165A1 (en) 2012-07-19
CA2783678A1 (en) 2011-06-16
CN102884082A (zh) 2013-01-16
BR112012015852B1 (pt) 2020-12-29
HRP20170016T1 (hr) 2017-02-24
CY1118407T1 (el) 2017-06-28
LT2510002T (lt) 2016-11-25
ME02577B (me) 2017-06-20
ZA201204214B (en) 2014-08-27
EP2510002A1 (en) 2012-10-17
CA2783513A1 (en) 2011-06-16
AU2010330161A1 (en) 2012-07-05
EA201200851A1 (ru) 2013-01-30
TW201130504A (en) 2011-09-16
TW201130505A (en) 2011-09-16
AR079351A1 (es) 2012-01-18
AU2010330161B2 (en) 2015-07-09
AR079641A1 (es) 2012-02-08
WO2011069797A1 (en) 2011-06-16
KR20120112528A (ko) 2012-10-11
ES2603352T3 (es) 2017-02-27
CL2012001540A1 (es) 2013-01-18
BR112012015852A2 (pt) 2017-05-23
IL220149A0 (en) 2012-07-31
US20130129739A1 (en) 2013-05-23
CY1118209T1 (el) 2017-06-28
BR112012015852A8 (pt) 2017-06-27
EP2510003A1 (en) 2012-10-17
CN102858804A (zh) 2013-01-02
EP2332995A1 (en) 2011-06-15
EP2567978A1 (en) 2013-03-13
HK1180354A1 (en) 2013-10-18
PE20121360A1 (es) 2012-10-11
WO2011069795A1 (en) 2011-06-16
PL2510002T3 (pl) 2017-02-28
CR20120312A (es) 2012-08-27
KR101765968B1 (ko) 2017-08-08
JP2015180690A (ja) 2015-10-15
JP2013513362A (ja) 2013-04-22
WO2011069795A4 (en) 2011-08-18
EP2510004A1 (en) 2012-10-17
CA2783610C (en) 2018-10-30
EP2510005A1 (en) 2012-10-17
RS55589B1 (sr) 2017-06-30
AR079348A1 (es) 2012-01-18
CA2783654A1 (en) 2011-06-16
IN2012DN05078A (es) 2015-10-23
WO2011069799A1 (en) 2011-06-16
PE20121561A1 (es) 2012-11-25
US20130272968A1 (en) 2013-10-17
HUE031631T2 (en) 2017-07-28
EP2510006A1 (en) 2012-10-17
EP2567977A1 (en) 2013-03-13
EP2510002B1 (en) 2016-08-24
BR112012014048A2 (pt) 2017-10-31
PL2510006T3 (pl) 2017-06-30
CN102947338A (zh) 2013-02-27
EA201200860A1 (ru) 2013-01-30
JP6199930B2 (ja) 2017-09-20
JP2013513365A (ja) 2013-04-22
CN102858803A (zh) 2013-01-02
SI2510002T1 (sl) 2016-12-30
NZ600511A (en) 2014-01-31
KR101790366B1 (ko) 2017-10-26
CU20120092A7 (es) 2012-10-15
EP2567979A1 (en) 2013-03-13
EP2510006B1 (en) 2016-11-09
PT2510002T (pt) 2016-11-23
US9649374B2 (en) 2017-05-16
MX2012006620A (es) 2012-06-21
TWI487536B (zh) 2015-06-11
EA028678B1 (ru) 2017-12-29
DK2510002T3 (en) 2016-11-28
IL220149A (en) 2017-09-28
ECSP12011966A (es) 2012-07-31
AU2010330165B2 (en) 2015-07-16
EP2567980A1 (en) 2013-03-13
JP2013513361A (ja) 2013-04-22
IN2012DN05082A (es) 2015-10-09
JP6066474B2 (ja) 2017-01-25
CA2783514A1 (en) 2011-06-16
KR20120112527A (ko) 2012-10-11
US20130171147A1 (en) 2013-07-04
EP2510007A1 (en) 2012-10-17
CN102947338B (zh) 2015-11-25
RS55277B1 (sr) 2017-02-28
TN2012000294A1 (en) 2013-12-12
WO2011069796A1 (en) 2011-06-16
TWI508744B (zh) 2015-11-21
US20120321632A1 (en) 2012-12-20
JP2013513364A (ja) 2013-04-22
HRP20161401T1 (hr) 2016-12-16
US9241989B2 (en) 2016-01-26
PE20171134A1 (es) 2017-08-09
SG181511A1 (en) 2012-07-30
EP2570435A1 (en) 2013-03-20
CU23973B1 (es) 2013-12-27
CA2783651A1 (en) 2011-06-16
EP2570436A1 (en) 2013-03-20
TW201138817A (en) 2011-11-16
PH12012501131A1 (en) 2017-08-23
LT2510006T (lt) 2016-12-12
CN102741291A (zh) 2012-10-17
HK1180700A1 (en) 2013-10-25
MX339343B (es) 2016-05-20
US20120315276A1 (en) 2012-12-13
US20130022606A1 (en) 2013-01-24
TW201130506A (en) 2011-09-16
DOP2012000160A (es) 2012-09-30
AR079352A1 (es) 2012-01-18
ZA201204213B (en) 2014-08-27
WO2011069798A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
CR20190319A (es) ANTICUERPOS CONTRA EL INHIBIDOR DEL ACTIVADOR DE PLASMINÓGENO TIPO 1 (PAI-1) Y USOS DE LOS MISMOS (Divisional 2016-0117)
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2021002491A1 (es) Receptores de células t mage a4
CL2009001277A1 (es) Anticuerpo que enlaza especificamente el flt3 humano; fragmento de cualquiera de los anticuerpos antes dichos; acido polinucleico aislado; vector de expresion; celula recombinante; composicion farmaceutica y sus usos; producto que contiene el anticuerpo para tratar cancer
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
MX388904B (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
UY33379A (es) Compuestos de morfolina
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
CL2011002417A1 (es) Anticuerpo especifico para fcrh5, receptor de superficie celular con homologia con las familias del receptor fc; anticuerpo anti-fcrh5 humanizado; polinucleotido que lo codifica; vector; celular huesped; metodo de obtencion; inmunoconjugado; composicion farmaceutica; y su uso para tratar cancer.
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
CL2011001578A1 (es) Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña.
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2012000238A1 (es) Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b.
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.